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Current thinking is that Ménière’s disease (or, more 
accurately, Ménière’s syndrome) is a phenotype of 
unstable or erratic inner ear hearing and vestibular 
function that arises from failure of one or more of the 
many inner ear homoeostatic systems that regulate 
endolymph and perilymph, aﬀ erent and eﬀ erent nerve 
signalling, and blood ﬂ ow.1 Clinically, the ﬂ uctuating 
and progressive sensorineural hearing loss tends to 
be relatively resistant to treatment (ie, progressive), 
but the episodic vertigo is usually quite responsive 
to treatment. The combination of diet and lifestyle 
adjustments to avoid stressing fragile homoeostatic 
systems plus diuretic medication to aid with inner ear 
ionic gradient management can control or eliminate 
Ménière’s vertigo attacks in over 90% of patients.2 
However, a troublesome group remains: 5–10% of all 
patients with Ménière’s disease are not responsive to 
these conservative and medical interventions and need 
more aggressive treatment. Nowadays, this most often 
means intratympanic drug treatment.
In The Lancet, Mitesh Patel and colleagues3 present 
results of a double-blind comparative eﬀ ectiveness trial 
of intratympanic methylprednisolone (n=30) versus 
intratympanic gentamicin (n=30) on intractable vertigo 
attacks in patients with unilateral Ménière’s disease. 
The two treatments were equally eﬀ ective at reducing 
vertigo attacks; the mean number of vertigo attacks in 
the ﬁ nal 6 months compared with the 6 months before 
the ﬁ rst injection (primary outcome) decreased from 19·9 
(SD 16·7) to 2·5 (5·8; 87% reduction) in the gentamicin 
group and from 16·4 (12·5) to 1·6 (3·4; 90% reduction) 
in the methylprednisolone group (diﬀ erence –0·9, 
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However, we suspect that this is probably representative 
of real world practice.
So what is the clinician to learn from this trial that 
might have an impact on practice? If a patient is a good 
surgical candidate, CABG should remain the mainstay of 
treatment. Although survival is the same, the incidence 
of clinically apparent myocardial infarction and need 
for repeat revascularisation and recurrence of angina is 
higher with PCI. In patients who are not good surgical 
candidates, PCI is a reasonable alternative to CABG, albeit 
with a higher incidence of subsequent clinical events.
So is this the ﬁ nal answer? Probably not, as additional 
questions are likely to be raised as new analyses are 
performed. All patients in NOBLE will be followed up at 
5 years and 10 years, which will add additional valuable 
information. Furthermore, with the results of the EXCEL 
Trial imminent, further light (or confusion) might be 
shed on the issue of disease management. 
Should the revascularisation guidelines change on the 
basis of the results of this trial? In the ACC/AHA and ESC 
Guidelines, CABG is a COR/LOE I B recommendation for 
left main revascularisation and PCI is either a I B, IIa B, 
or III B recommendation based on Syntax score tertile.5,6 
This trial will add to the level of evidence but is not 
suﬃ  cient by itself to change present guidelines. 
Finally, can we expect further trials of comparative 
eﬀ ectiveness between the two treatment strategies? 
With trials of this magnitude costing tens of millions of 
US dollars and none underway to our knowledge, it is 
probable that these two trials will serve as the evidence 
base for management of patients with left main disease 
for the foreseeable future. 
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95% CI –3·4 to 1·6). Secondary outcomes related to 
other vestibular symptoms and hearing loss (all p>0·05) 
were also similar between groups, as was the occurrence 
of adverse events (three in each group). Intratympanic 
corticosteroid treatment for Ménière’s disease is based on 
the supposition that Ménière’s disease symptoms arise 
from an inﬂ ammatory or other reversible mechanism 
that could be favourably altered by administration of 
corticosteroid. Tens or hundreds of inner ear proteins have 
steroid-binding capability. In fact, it would be startling if 
administration of corticosteroid to the inner ear didn’t 
have an eﬀ ect of some kind. But what is the likelihood that 
application of such a so-called blunt instrument would do 
more good than harm? We have learned empirically over 
the past 30 years that intratympanic corticosteroid is safe, 
producing few side-eﬀ ects and virtually no hearing loss 
or vestibular damage. It won’t hurt and it might help, so 
it has become a popular treatment despite the absence of 
strong evidence of eﬃ  cacy.
By contrast, gentamicin is a hair cell ototoxin. It is 
preferentially vestibulotoxic, typically causing much 
more vestibular than auditory damage. Administration 
of intratympanic gentamicin to patients with Ménière’s 
disease is based on the notion that the patient’s vestibular 
symptoms are due to the damaged and distorted 
vestibular signals emanating from their damaged 
ear and that they are better oﬀ  with no signal than 
with a damaged and distorted signal. The objective of 
intratympanic gentamicin is to weaken vestibular signals 
in the Ménière’s ear to the point at which they are no 
longer strong enough to generate a vertigo attack. This 
objective is achieved in about 90% of treated patients. 
However, there is a price to pay in the form of 1–2 months 
of, and possibly permanent, disequilibrium and about 
20% risk of further hearing loss in the treated ear.
Patel and colleagues’ study,3 by adhering to stringent 
methods, oﬀ ers robust evidence that both of these 
treatments have substantial eﬃ  cacy, with each achieving 
about 90% reduction of vertigo attacks. There was no 
placebo control group to provide greater certainty that the 
treatment eﬀ ects were not just the natural course of this 
relapsing–remitting disease. However, the data showed a 
dramatic drop in vertigo frequency soon after treatment 
and no reactivation over 24 months of follow-up, which 
is persuasive evidence of a true treatment eﬀ ect. One 
treatment aims to modulate an underlying, and unknown, 
disease process and the other treatment is ablative, aiming 
to weaken or eliminate abnormal function in the damaged 
ear. The equivalence of outcome of these two treatments 
has shed no new light on the underlying mechanisms 
of Ménière’s disease, but will still have important clinical 
impact. Since we now know that either intratympanic 
corticosteroid or intratympanic gentamicin can be used 
to achieve vertigo control, the actual decision of which 
to use will be based on doctor and patient consideration 
of auditory and vestibular side-eﬀ ects, status of the 
contralateral ear, general health factors, and patient 
preference. Although most patients with Ménière’s disease 
gradually go deaf in their aﬀ ected ear, the best news for 
patients is that some combination of diet and lifestyle 
adjustments, diuretics, and intratympanic drug treatment 
can control or eliminate vertigo in 99% of cases. And 
there is always the surgical option of labyrinthectomy for 
patients who do not respond to intratympanic gentamicin.
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